DRREDDY

Dr. Reddy's Laboratories Limited

Global generics and APIs, now building biosimilars and peptides

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

drreddys.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-19

Stock price
₹1242.50
Market cap
1,03,573 Cr
Stock P/E
32.1
P/B
2.73
Dividend yield
0.6%
ROE (FY26)
11.0%
ROCE (FY26)
13.0%
Operating margin (FY26)
13.0%
Debt / equity (FY26)
0.17
OCF / EBITDA (FY26)
87.9%
OCF / EBITDA (3Y)
64.8%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Dr. Reddy's makes and sells generic medicines, active pharmaceutical ingredients and other pharma products to patients, pharmacies and drug makers in the US, India, Europe and emerging markets.

Company snapshot

7thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Segment mix

Reportable segments as of 2024-12-31 (Standalone). Revenue share = segment revenue ÷ total revenue.

Largest segment: 89.1% of revenue

SegmentRevenue shareRevenuePBTAssets
Global Generics
89.1%
15,632 Cr5,474 Cr—
Pharmaceutical Services and Active Ingredients
14.1%
2,476 Cr10 Cr—
Proprietary Products
0.8%
137 Cr137 Cr—

Shares add up to 104% because segment revenues are before inter-segment eliminations.

What we see

Positives
  • ✓Debt-to-equity of 0.17x — the company is largely funded by its own money, not borrowed funds.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales6,903 Cr7,237 Cr7,114 Cr7,696 Cr8,038 Cr8,381 Cr8,528 Cr8,572 Cr8,828 Cr8,753 Cr7,546 Cr8,100 Cr
Operating expenses (approx.)4,894 Cr5,214 Cr5,283 Cr5,566 Cr5,962 Cr6,108 Cr6,531 Cr6,399 Cr6,818 Cr6,866 Cr7,164 Cr7,240 Cr
EBITDA2,008 Cr2,023 Cr1,831 Cr2,130 Cr2,077 Cr2,273 Cr1,998 Cr2,174 Cr2,010 Cr1,888 Cr383 Cr860 Cr
OPM %29.1%28.0%25.7%27.7%25.8%27.1%23.4%25.4%22.8%21.6%5.1%10.6%
Other income315 Cr216 Cr198 Cr187 Cr308 Cr150 Cr522 Cr290 Cr324 Cr269 Cr475 Cr355 Cr
Interest35 Cr39 Cr59 Cr60 Cr76 Cr82 Cr66 Cr83 Cr91 Cr94 Cr106 Cr126 Cr
Depreciation376 Cr374 Cr368 Cr381 Cr397 Cr471 Cr455 Cr476 Cr505 Cr521 Cr557 Cr537 Cr
Profit before tax1,917 Cr1,829 Cr1,605 Cr1,883 Cr1,917 Cr1,874 Cr2,005 Cr1,905 Cr1,745 Cr1,543 Cr200 Cr553 Cr
Tax %22.7%24.5%18.4%26.0%30.0%25.1%20.9%26.0%23.4%22.9%-10.8%21.3%
Net profit1,482 Cr1,381 Cr1,310 Cr1,392 Cr1,342 Cr1,404 Cr1,587 Cr1,410 Cr1,337 Cr1,190 Cr221 Cr436 Cr
EPS (₹)₹89.09₹82.94₹78.66₹83.61₹15.08₹16.97₹19.12₹17.04₹16.18₹14.53₹2.65₹5.33

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales14,196 Cr14,281 Cr15,448 Cr17,517 Cr19,048 Cr21,545 Cr24,670 Cr28,011 Cr32,644 Cr33,700 CrSign in free for the trailing twelve months
Operating expenses (approx.)11,724 Cr11,930 Cr12,270 Cr15,047 Cr15,178 Cr17,778 Cr18,321 Cr20,078 Cr24,097 Cr27,247 CrSign in free for the trailing twelve months
EBITDA2,472 Cr2,351 Cr3,178 Cr2,470 Cr3,870 Cr3,768 Cr6,349 Cr7,933 Cr8,547 Cr6,454 CrSign in free for the trailing twelve months
OPM %17.4%16.5%20.6%14.1%20.3%17.5%25.7%28.3%26.2%19.1%Sign in free for the trailing twelve months
Other income172 Cr155 Cr338 Cr621 Cr291 Cr484 Cr1,056 Cr894 Cr1,097 Cr1,358 CrSign in free for the trailing twelve months
Interest63 Cr79 Cr89 Cr98 Cr97 Cr96 Cr143 Cr171 Cr283 Cr374 CrSign in free for the trailing twelve months
Depreciation1,027 Cr1,077 Cr1,135 Cr1,163 Cr1,229 Cr1,165 Cr1,250 Cr1,470 Cr1,704 Cr2,059 CrSign in free for the trailing twelve months
Profit before tax1,589 Cr1,385 Cr2,336 Cr1,886 Cr2,884 Cr3,061 Cr6,049 Cr7,201 Cr7,680 Cr5,393 CrSign in free for the trailing twelve months
Tax %18.7%31.6%16.5%-7.4%32.3%28.7%25.5%22.5%25.4%22.9%Sign in free for the trailing twelve months
Net profit1,292 Cr947 Cr1,950 Cr2,026 Cr1,952 Cr2,183 Cr4,507 Cr5,578 Cr5,725 Cr4,158 CrSign in free for the trailing twelve months
EPS (₹)₹77.53₹57.08₹117.53₹122.22₹117.67₹131.57₹271.47₹335.22₹67.89₹50.41Sign in free for the trailing twelve months
Dividend payout %————21.2%19.0%11.0%11.9%11.6%16.0%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital83 Cr83 Cr83 Cr83 Cr83 Cr83 Cr83 Cr83 Cr83 Cr84 Cr
Reserves12,179 Cr12,489 Cr13,941 Cr15,516 Cr17,559 Cr19,129 Cr23,203 Cr28,171 Cr33,466 Cr37,808 Cr
Borrowings4,908 Cr5,065 Cr3,413 Cr1,784 Cr2,944 Cr3,283 Cr1,347 Cr1,652 Cr4,185 Cr6,294 Cr
Other liabilities4,647 Cr4,908 Cr5,030 Cr5,843 Cr6,031 Cr7,252 Cr7,652 Cr8,957 Cr11,315 Cr13,599 Cr
Total liabilities21,817 Cr22,544 Cr22,466 Cr23,225 Cr26,617 Cr29,747 Cr32,285 Cr38,864 Cr49,427 Cr58,123 Cr
Fixed assets (net)5,028 Cr4,973 Cr4,913 Cr4,778 Cr4,732 Cr4,887 Cr5,654 Cr6,249 Cr7,298 Cr10,078 Cr
CWIP610 Cr768 Cr473 Cr436 Cr954 Cr1,280 Cr975 Cr1,351 Cr2,399 Cr1,460 Cr
Investments2,110 Cr2,298 Cr2,587 Cr2,678 Cr2,808 Cr2,616 Cr4,986 Cr4,931 Cr4,051 Cr5,285 Cr
Inventories2,853 Cr2,909 Cr3,358 Cr3,507 Cr4,541 Cr5,088 Cr4,867 Cr6,355 Cr7,109 Cr7,653 Cr
Trade receivables3,799 Cr4,053 Cr3,987 Cr5,028 Cr4,964 Cr6,676 Cr7,249 Cr8,030 Cr9,042 Cr10,123 Cr
Cash & bank387 Cr264 Cr223 Cr205 Cr1,483 Cr1,485 Cr578 Cr711 Cr1,465 Cr1,537 Cr
Other assets7,031 Cr7,280 Cr6,926 Cr6,593 Cr7,135 Cr7,715 Cr7,976 Cr11,238 Cr18,062 Cr21,987 Cr
Total assets21,817 Cr22,544 Cr22,466 Cr23,225 Cr26,617 Cr29,747 Cr32,285 Cr38,864 Cr49,427 Cr58,123 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity—1,803 Cr2,870 Cr2,984 Cr3,570 Cr2,811 Cr5,887 Cr4,543 Cr4,643 Cr5,674 Cr
Cash from investing—-1,488 Cr-773 Cr-492 Cr-2,266 Cr-2,639 Cr-4,137 Cr-4,028 Cr-5,102 Cr-6,549 Cr
Cash from financing—-444 Cr-2,133 Cr-2,516 Cr-30 Cr-242 Cr-2,686 Cr-376 Cr1,186 Cr829 Cr
Net cash flow—-129 Cr-35 Cr-24 Cr1,286 Cr3 Cr-907 Cr133 Cr749 Cr78 Cr
Free cash flow (OCF − Capex)—699 Cr2,033 Cr2,373 Cr2,314 Cr906 Cr4,001 Cr1,800 Cr1,203 Cr1,833 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %9.6%8.3%13.9%11.4%14.5%14.0%25.1%24.6%20.9%13.0%
ROE %10.5%7.5%13.9%13.0%11.1%11.4%19.4%19.7%16.7%11.0%
Debtor days971039410595113107105101109
Inventory days425402423429385430420517455429
Days payable157185172186153191196213170170
Cash conversion cycle365321345347326351331409387368
OCF / EBITDA %—76.7%90.3%120.8%92.3%74.6%92.7%57.3%54.3%87.9%
OCF / EBITDA % (3 years)———95.7%99.0%92.7%87.7%73.4%66.0%64.8%
Debt / equity0.400.400.240.110.170.170.060.060.120.17
Current ratio1.151.521.941.811.831.852.412.591.921.80
Net debt / EBITDA1.83—1.000.640.380.480.120.120.320.74